Pamidronate Disodium

帕米膦酸二纳

Report date: 2022/08/16 20:00:19
NME

Base Information

Drug NamePamidronate Disodium
Drug Alias Name氨羟二磷酸二钠丙氨膦酸二钠帕米磷酸二钠帕米膦酸二钠阿可达 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFarnesyl diphosphate synthase inhibitorsBone resorption factor inhibitors
TargetsBone resorption factorFarnesyl diphosphate synthase
Therapy Area/IndicationsLow Back PainImmune System DiseasesHypercalcemia +[8] 
Global Approved IndicationsHypercalcemiaOsteitis DeformansBone Diseases, Metabolic
Approved Indications in ChinaHypercalcemia
Original Approved Country/TerritoryUnited States
Original Approved Date1991/10/31
Country/TerritoryUnited StatesDenmarkMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Neptunus Pharmaceutical Co Ltd
Inactive CompaniesEunice Kennedy Shriver National Institute Of Child Health And Human DevelopmentAarhus UniversityNational Institute Of Arthritis And Musculoskeletal And Skin Diseases +[5] 
Active IndicationsHypercalcemia
Inactive IndicationsLow Back PainImmune System DiseasesOsteitis Deformans +[7] 

Other Information

ATC CodeM05BA03
Related LinksWikipediaDrugBankKEGG